Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.

被引：0
|
作者：
Park, Seongjoon
Lee, Jae-Lyun
Park, Inkeun
Park, Kwonoh
Ahn, Yongchel
Ahn, Jin-Hee
Lee, Dae Ho
Song, Cheryn
Hong, Jun Hyuk
Kim, Choung-Soo
Ahn, Hanjong
机构：
[1] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Dept Urol, Asan Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15080
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Hai-Liang Zhang
    Xi-Nan Sheng
    Xue-Song Li
    Hong-Kai Wang
    Zhi-Hong Chi
    Zhi-Song He
    Ding-Wei Ye
    Jun Guo
    [J]. BMC Cancer, 17
  • [22] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Zhang, Hai-Liang
    Sheng, Xi-Nan
    Li, Xue-Song
    Wang, Hong-Kai
    Chi, Zhi-Hong
    He, Zhi-Song
    Ye, Ding-Wei
    Guo, Jun
    [J]. BMC CANCER, 2017, 17
  • [23] Five-year survival analysis of interferon-a plus sorafenib versus sorafenib monotherapy as first-line treatment for metastatic clear cell renal cell carcinoma.
    Ding-Wei, Ye
    Hai-Lang, Zhang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [24] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [25] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
    Emilio, Mucino-Ortega
    Joaquin Federico, Mould-Quevedo
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
  • [26] ECONOMIC EVALUATION OF SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Prieto, V. A.
    Reyes, J. M.
    Lopez-Cabra, C.
    Diaz, J. A.
    Urrego-Novoa, J. R.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [27] The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma
    Kameda, Tomohiro
    Takayama, Tatsuya
    Sugihara, Toru
    Takeshima, Saki
    Yamazaki, Masahiro
    Komatsubara, Maiko
    Kamei, Jun
    Fujisaki, Akira
    Ando, Satoshi
    Kurokawa, Shinsuke
    Fujimura, Tetsuya
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (04) : 241 - 246
  • [28] Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma.
    Suarez, C.
    Gallardo, E.
    Rodon Ahnert, J.
    Guix, M.
    Bonfill, T.
    Pons, F.
    Beltran, M.
    Moya, I.
    Galtes, S.
    Albanell, J.
    Carles, J.
    Bellmunt, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Efficacy and toxicity of sunitinib in renal insufficiency patients with metastatic renal cell carcinoma.
    Kim, Ki Hyang
    Rha, Sun Young
    Kim, Ho Young
    Kim, Hye Ryun
    Sun, Jong-Mu
    Lim, Ho Yeong
    Lee, Hyo Jin
    Lee, Suee
    Bae, Woo Kyun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
    Badran, Ahmed
    Elshenawy, Mahmoud A.
    Shahin, Amgad
    Aljubran, Ali
    Alzahrani, Ahmed
    Eldali, Abdelmoneim
    Bazarbashi, Shouki
    [J]. JCO GLOBAL ONCOLOGY, 2020, 6 : 19 - 26
12345